NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis $5.15 -0.07 (-1.34%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About OptimizeRx Stock (NASDAQ:OPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OptimizeRx alerts:Sign Up Key Stats Today's Range$5.13▼$5.2650-Day Range$5.15▼$8.4152-Week Range$5.13▼$16.65Volume116,552 shsAverage Volume127,221 shsMarket Capitalization$94.36 millionP/E RatioN/ADividend YieldN/APrice Target$14.50Consensus RatingModerate Buy Company OverviewOptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.Read More… He made 1,303,329 in 12 months after Biden won… (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why OptimizeRx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreOPRX MarketRank™: OptimizeRx scored higher than 52% of companies evaluated by MarketBeat, and ranked 500th out of 667 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOptimizeRx has only been the subject of 2 research reports in the past 90 days.Read more about OptimizeRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about OptimizeRx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.75% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in OptimizeRx has recently increased by 8.71%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.75% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in OptimizeRx has recently increased by 8.71%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.77 News SentimentOptimizeRx has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for OptimizeRx this week, compared to 2 articles on an average week.Search Interest7 people have searched for OPRX on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesOptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ETOctober 31 at 7:30 AM | globenewswire.comOptimizeRx: A Strong Buy on Client Commitments and Growth PotentialSeptember 11, 2024 | markets.businessinsider.comCountdown to the biggest trade of my 25 yr careerTim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.November 2, 2024 | Timothy Sykes (Ad)OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total ValueSeptember 10, 2024 | globenewswire.comOptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare AudiencesSeptember 9, 2024 | globenewswire.comOptimizeRx Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 12, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their OptimizeRx Corporation (NASDAQ:OPRX) Price Target To US$15.79August 11, 2024 | finance.yahoo.comOptimizeRx Corporation (OPRX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comSee More Headlines OPRX Stock Analysis - Frequently Asked Questions How have OPRX shares performed this year? OptimizeRx's stock was trading at $14.31 at the beginning of the year. Since then, OPRX shares have decreased by 64.0% and is now trading at $5.15. View the best growth stocks for 2024 here. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.11. The company earned $18.81 million during the quarter, compared to analyst estimates of $20.47 million. OptimizeRx had a negative net margin of 21.53% and a negative trailing twelve-month return on equity of 5.97%. Who are OptimizeRx's major shareholders? OptimizeRx's top institutional shareholders include Rice Hall James & Associates LLC (3.36%), Essex Investment Management Co. LLC (1.32%), Janney Montgomery Scott LLC (0.57%) and Greenwood Capital Associates LLC (0.37%). Insiders that own company stock include William J Febbo, James Paul Lang, Marion Odence-Ford, Stephen L Silvestro, Edward Stelmakh, Ellen O'connor Vos, Patrick D Spangler and Miriam J Paramore. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings8/08/2024Today11/02/2024Next Earnings (Confirmed)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryBusiness Services Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$14.50 High Stock Price Target$18.50 Low Stock Price Target$11.00 Potential Upside/Downside+181.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,570,000.00 Net Margins-21.53% Pretax Margin-31.60% Return on Equity-5.97% Return on Assets-4.42% Debt Debt-to-Equity Ratio0.27 Current Ratio3.07 Quick Ratio3.07 Sales & Book Value Annual Sales$83.20 million Price / Sales1.13 Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / Book0.74Miscellaneous Outstanding Shares18,322,000Free Float17,204,000Market Cap$94.36 million OptionableOptionable Beta1.27 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:OPRX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.